India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.
US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, it has since become a global blockbuster.
While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its effectiveness in obesity management come out in 3 months.
Tirzepatide is a type 2 diabetes and obesity drug sold by US firm Eli Lilly under the brand names Mounjaro and Zepbound. It may take around 6 months for it to be launched in India.
Pharma giants were responding to petition in Kerala HC seeking compulsory licences for their HER2-negative breast cancer drugs, which would allow cheaper, generic versions to be made.
Patients who got a weekly injection of the experimental anti-obesity drug retatrutide lost up to 24 per cent of their body weight in 48 weeks, show phase-2 trials published this week.
BHL says it can produce Baricitinib for as cheap as Rs 14 (for 1mg). US pharma giant Eli Lilly, which holds exclusive licence for the drug, manufactures it at an average cost of Rs 3,230.
‘The tirade against capitalism is wholly unfounded. Capitalism as it has shaped during the past quarter of a century is a far better method of developing the economic resources of any country,’ wrote DN Hosali in 1956.
Mini deal will likely see no cut in 10% baseline tariff on Indian exports announced by Trump on 2 April, it is learnt, but additional 26% tariffs are set to be reduced.
India-Russia JV is also racing to deliver 7,000 more AK-203 assault rifles by 15 Aug. These are currently being made with 50% indigenisation and this will surge to 100% by 31 December.
Public, loud, upfront, filled with impropriety and high praise sometimes laced with insults. This is what we call Trumplomacy. But the larger objective is the same: American supremacy.
COMMENTS